Successful treatment of mixed-type autoimmune hemolytic anemia with rituximab in a child following liver transplantation

Wolfram Haller; Jonathan Hind; Sue Height; Ragai Mitry; Anil Dhawan

doi:10.1111/j.1399-3046.2009.01128.x

Successful treatment of mixed-type autoimmune hemolytic anemia with rituximab in a child following liver transplantation

Pediatr Transplant. 2010 May;14(3):E20-5. doi: 10.1111/j.1399-3046.2009.01128.x. Epub 2009 Feb 20.

Authors

Wolfram Haller¹, Jonathan Hind, Sue Height, Ragai Mitry, Anil Dhawan

Affiliation

¹ Paediatric Liver Centre, King's College Hospital NHS Foundation Trust, Denmark Hill, London, UK. wolframhaller@nhs.net

PMID: 19254271
DOI: 10.1111/j.1399-3046.2009.01128.x

Abstract

Development of a severe form of mixed-type AIHA after orthotopic liver transplantation is a rare, but a life-threatening event. We report a case of mixed-type AIHA that developed in a child after hepatocyte and living-related orthotopic liver transplantation for factor VII deficiency.

Publication types

Case Reports

MeSH terms

Anemia, Hemolytic, Autoimmune / drug therapy*
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived
Humans
Immunologic Factors / therapeutic use*
Infant
Liver Transplantation
Male
Postoperative Complications / drug therapy*
Rituximab

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Immunologic Factors
Rituximab